Pre-market hot trades in US stocks: AMASS Brands up 10.19% in pre-market; Starbucks up 7.07% in pre-market
I'm LongbridgeAI, I can summarize articles.AMASS Brands pre-market up 10.19%; Starbucks pre-market up 7.07%; Nuwellis pre-market up 102.63%; T3 Defense pre-market up 72.42%; China Su Xuan Tang Pharmaceutical pre-market up 59.62%
Pre-market Hot Trades in US Stocks
AMASS Brands is up 10.19% in pre-market trading. Based on recent key news:
- On July 27, AMASS Brands released an important announcement through the EDGAR system of the U.S. Securities and Exchange Commission, regarding adjustments to the company's future development strategy and the launch of new product lines. This announcement boosted market confidence in the company's growth potential, driving the stock price up 10.19% in pre-market trading. Source: EDGAR system announcement, market response to new product lines is positive.
Starbucks is up 7.07% in pre-market trading. Based on recent key news:
-
On July 30, Starbucks announced quarterly results with net revenue of $9.3 billion, exceeding expectations, and net profit of $1.05 billion, leading to a 6.6% increase in after-hours stock price. Starbucks raised its full-year adjusted earnings per share outlook, expecting an adjusted operating margin of over 11% for the year. Source: Viewpoint Network
-
On July 30, Starbucks reported third-quarter revenue of $9.323 billion, with profits soaring 87% to $1.045 billion, and Non-GAAP earnings per share of $0.85, surpassing market expectations. After the earnings announcement, Starbucks' after-hours stock price rose 4.67%. Source: Hong Kong Economic Journal
-
On July 30, Starbucks' global same-store sales increased by 7.9%, exceeding the market expectation of 5.7%. Starbucks raised its full-year performance guidance, expecting global same-store sales to grow close to 6%. Source: Reuters, Starbucks' performance exceeded expectations, stock price rose.
Top Gainers in Pre-market US Stocks
Nuwellis is up 102.63% in pre-market trading. Based on recent key news:
-
On July 27, Nuwellis announced a preliminary revenue growth of 14% for the second quarter of 2026, driving a significant increase in stock price. The company expects a 20% year-over-year revenue growth in the first half of 2026, mainly due to the commercial success of the Aquadex ultrafiltration platform.
-
On July 27, Nuwellis released unaudited preliminary revenue data showing a 14% year-over-year revenue growth for the second quarter of 2026. The company expects a 20% year-over-year revenue growth in the first half of 2026, further enhancing market confidence.
-
On July 27, Nuwellis announced a preliminary revenue growth of 14% for the second quarter of 2026 and expects a 20% year-over-year revenue growth in the first half of 2026. This growth is primarily attributed to the continued commercial success of the Aquadex ultrafiltration platform. The market reacted positively to the company's revenue growth expectations.
T3 Defense is up 72.42% in pre-market trading. Based on recent key news:
-
On July 29, T3 Defense completed a 1-for-125 reverse stock split, reducing the float to 1.12 million shares, triggering a technical short squeeze. At the same time, the company made operational progress and achieved contract delivery in its Project 35 in the anti-drone technology field, X S.E Security and Defense Ltd. acquires 16.67% equity in the company in exchange for Project 35 equity, boosting market confidence.
-
On July 28, T3 Defense's subsidiary completed the delivery of an automated composite material production line to a major Israeli manufacturer, further expanding its influence in the high-demand anti-drone technology sector. SEC filings show that X S.E. Security and Defense Ltd. acquired 16.67% equity in the company, enhancing investor interest.
-
On July 28, T3 Defense's stock price rose by 130.76%, closing at $30.23, due to the company's expansion in the high-demand anti-drone technology sector and the entry of strategic investors, with a positive market response. The demand for anti-drone technology is high, and the market is highly volatile.
China Su Xuan Tang Pharmaceutical, pre-market up 59.62%, has no significant news recently. Trading is active, with clear capital flows. Considering the sector and industry trends, the stock shows significant volatility, and specific reasons need further observation
